The Biotech Stock That's Too Risky for Most Investors

The artificial intelligence (AI) revolution has the potential to alter just about every business operation for the better. One area where investors are extra excited about productivity improvements is the drug development business.The vast majority of experimental drugs that enter clinical trials never become marketable products, but by applying AI to the discovery process, Recursion Pharmaceuticals (NASDAQ: RXRX) plans to become a top-performing biotech stock.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool